Setileuton

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSetileuton
Drug Alias Name司替鲁彤setileutonum塞替留通MK-0633
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionArachidonate 5-lipoxygenase inhibitors
TargetsArachidonate 5-lipoxygenase
Therapy Area/IndicationsAtherosclerosisPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck & Co IncMerck Sharp & Dohme LLCMerck Sharp & Dohme (China) Co Ltd
Active IndicationsN/A
Inactive IndicationsAtherosclerosisPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksKEGG